02-4091. Mylan Pharmaceuticals et al.; Withdrawal of Approval of 34 Abbreviated New Drug Applications
-
Start Preamble
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Notice.
SUMMARY:
The Food and Drug Administration (FDA) is withdrawing approval of 34 abbreviated new drug applications (ANDAs). The holders of the applications notified the agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.
DATES:
Effective March 22, 2002.
Start Further InfoFOR FURTHER INFORMATION CONTACT:
Florine P. Purdie, Center for Drug Evaluation and Research (HFD-7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-2041.
End Further Info End Preamble Start Supplemental InformationSUPPLEMENTARY INFORMATION:
The holders of the applications listed in the table in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications. The applicants have also, by their request, waived their opportunity for a hearing.
ANDA No. Drug Applicant 61-530 Penicillin V Potassium Tablets USP, 250 milligrams (mg) and 500 mg. Mylan Pharmaceuticals, Inc., 781 Chestnut Ridge Rd., P.O. Box 4310 Morgantown, WV 26504-4310. 61-829 Ampicillin for Oral Suspension USP, 125 mg/5 milliliters (mL) and 250mg/5 mL. Do. 62-067 Amoxicillin Capsules USP, 250 mg and 500 mg Do. 62-104 Neomycyin Sulfate with Hydrocortisone Ointment USP, 0.35% and 1%. Clay-Park Laboratories, Inc., 1700 Bathgate Ave., Bronx, NY 10457. 62-280 Nystatin and Triamcinolone Acetonide Ointment USP Do. 62-372 Mezlin (sterile mezlocillin sodium) Bayer Corp. Pharmaceutical Division, 400 Morgan Lane, West Haven, CT 06516. 62-697 Mezlin (sterile mezlocillin sodium) Do. 71-099 Bromatapp ER (brompheniramine maleate/phenylpropanolamine hydrochloride (HCl)) Extended-Release Tablets, 12 mg/75 mg. Copley Pharmaceuticals, Inc., 25 John Rd. Canton, MA 02021. 71-551 Flurazepam HCl Capsules USP, 30 mg Purepac Pharmaceutical Co., 200 Elmora Ave., Elizabeth, NJ 07207. 71-927 Flurazepam HCl Capsules USP, 15 mg Do. 72-027 Fentanyl Citrate and Droperidol Injection AstraZeneca LP, 1800 Concord Pike, P.O. Box 8355, Wilmington, DE 19803-8355. 72-070 Nalbuphine HCl Injection USP, 10 mg/mL Do. 72-073 Nalbuphine HCl Injection USP, 20 mg/mL Do. 72-921 Prazosin HCl Capsules USP, 2 mg Purepac Pharmaceutical Co. 72-991 Prazosin HCl Capsules USP, 1 mg Do. 72-992 Prazosin HCl Capsules USP, 5 mg Do. 73-690 Calcitonin-Salmon Injection, 200 international units/mL AstraZeneca LP. Start Printed Page 7703 74-579 Betamethasone Dipropionate Cream USP, 0.05% (base) Clay-Park Laboratories, Inc. 75-263 Midazolam HCl Injection, 5 mg (base)/mL AstraZeneca LP. 75-348 Ketorolac Tromethamine Injection USP, 15 mg/mL and 30 mg/mL. Apothecon, Inc., P.O. Box 4500, Princeton, NJ 08543-4500. 75-355 Labetalol HCl Injection USP, 5 mg/mL Do. 75-620 Midazolam HCl Injection, 1 mg (base)/mL and 5 mg (base)/mL. Do. 75-641 Midazolam HCl Injection, 5 mg (base)/mL Do. 75-642 Bisoprolol Fumarate and Hydrochlorothiazide Tablets Do. 75-707 Famotidine Injection, 10 mg/mL Do. 75-708 Famotidine Injection, 10 mg/mL (preservative free) Do. 83-115 Niacin Tablets USP, 500 mg Impax Laboratories, Inc., 30831 Huntwood Ave., Hayward, CA 94544. 84-968 Nitrofurazone Ointment USP, 0.2% Clay-Park Laboratories, Inc. 85-130 Nitrofurazone Topical Solution USP, 0.2% Do. 86-424 Triple Sulfa Vaginal Cream Altana Inc., 60 Baylis Rd., Melville, NY 11747. 86-810 Fluocinolone Acetonide Cream USP, 0.01% Clay-Park Laboratories, Inc. 86-811 Fluocinolone Acetonide Cream USP, 0.025% Do. 89-784 Meperidine HCl Injection USP, 50 mg/mL AstraZeneca LP. 89-788 Meperidine HCl Injection USP, 1,000 mg/mL Do. Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director, Center for Drug Evaluation and Research (21 CFR 5.82), approval of the applications listed in the table in this document, and all amendments and supplements thereto, is hereby withdrawn, effective March 22, 2002.
Start SignatureDated: February 12, 2002.
Steven K. Galson,
Deputy Director, Center for Drug Evaluation and Research.
[FR Doc. 02-4091 Filed 2-19-02; 8:45 am]
BILLING CODE 4160-01-S
Document Information
- Effective Date:
- 3/22/2002
- Published:
- 02/20/2002
- Department:
- Food and Drug Administration
- Entry Type:
- Notice
- Action:
- Notice.
- Document Number:
- 02-4091
- Dates:
- Effective March 22, 2002.
- Pages:
- 7702-7703 (2 pages)
- Docket Numbers:
- Docket No. 02N-0035
- PDF File:
- 02-4091.pdf